Alan Hutson

Ofatumumab plus HyperCVAD/HD‐MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study

P. Wallace, F. Hernandez-Ilizaliturri, S. Sait, 2022, Cancer.

Injury rates in house league, select, and representative youth ice hockey.

J. Leddy, B. Willer, S. Darling, 2005, Medicine and science in sports and exercise.

Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC

Daniel T. Fisher, P. Wallace, I. Puzanov, 2022, Frontiers in Oncology.

Not all vaping is the same: differential pulmonary effects of vaping cannabidiol versus nicotine

M. Goniewicz, Y. Thanavala, T. A. Bhat, 2023, Thorax.

Reprogramming the tumor microenvironment leverages CD8+ T cell responses to a shared tumor/self antigen in ovarian cancer

Jianmin Wang, A. Gambotto, K. Odunsi, 2023, Molecular therapy oncolytics.

Accuracy of self-reported tobacco use in newly diagnosed cancer patients

A. Hyland, A. Hutson, G. Warren, 2013, Cancer Causes & Control.

Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

W. Curry, E. Wong, M. Ahluwalia, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses

P. Danaher, C. Morrison, Song Liu, 2022, Science Translational Medicine.